Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
This is written in the approval document as:
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
Citation
Everolimus and Exemestane Therapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| Sensitivity (+) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane |